Rakovina Therapeutics Inc.

RKV

CA75103L1013

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 16:34:00 09/05/2024 BST			5-day change	1st Jan Change
0.085 ^CAD	-5.56%		0.00%	0.00%

05-08	Rakovina Therapeutics Announces Extensions and Expansions of Strategic Collaborations to Support AI Research	CI
04-09	Rakovina Therapeutics Presents At American Association Of Cancer Research Annual Meeting	MT

Rakovina Therapeutics Inc. Reports Earnings Results for the Second Quarter Ending June 30, 2021

August 26, 2021 at 02:00 pm

Rakovina Therapeutics Inc. reported earnings results for the second quarter ending June 30, 2021. For the quarter, the company reported a net loss of $835,062.

Latest news about Rakovina Therapeutics Inc.

Rakovina Therapeutics Announces Extensions and Expansions of Strategic Collaborations to Support AI Research	05-08	CI
Rakovina Therapeutics Presents At American Association Of Cancer Research Annual Meeting	04-09	MT
Rakovina Therapeutics Announces Appointment to Scientific Advisory Board	11-27	MT
Rakovina Therapeutics Appoints Prof. Artem Cherkasov to the Scientific Advisory Board	11-27	CI
Rakovina Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-26	CI
Rakovina Therapeutics Inc. Announces Appointment of Prof. Petra Hamerlik as New Scientific Advisory Board Member	11-20	CI
Rakovina Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	28/08/23	CI
Rakovina Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	29/05/23	CI
Rakovina Therapeutics Inc. announced that it has received CAD 1.5 million in funding	28/05/23	CI
Rakovina Therapeutics Inc. announced that it expects to receive CAD 1.5 million in funding	01/05/23	CI
Rakovina Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	27/04/23	CI
Rakovina Therapeutics Announces Presentation of New kt-3000 Series Data at AACR Annual Meeting	20/04/23	MT
Rakovina Therapeutics Inc. Announces Presentation of New KT-3000 Series Data At AACR Annual Meeting	20/04/23	CI
Rakovina Therapeutics Receives Federal Funding to Accelerate Development of Novel Cancer Therapies	22/03/23	MT
Rakovina Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	15/11/22	CI
Rakovina Therapeutics Says Publication Highlights Activity of Dual PARP-HDAC Inhibitor in Models of Ewing Sarcoma	14/11/22	MT
Rakovina Therapeutics Presented Preclinical Data at Molecular Targets and Cancer Therapeutics Symposium in Barcelona	31/10/22	MT
Rakovina Therapeutics Second-Quarter Loss Narrows on Lower Spending	11/08/22	MT
Rakovina Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	09/08/22	CI
Rakovina Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	24/05/22	CI
Rakovina Therapeutics Presents Preclinical Data on its Novel kt-3000 Series at the 2022 AACR Special Conference on Sarcomas	11/05/22	CI
Rakovina Therapeutics Reports Q4 Net Loss of $751K	27/04/22	MT
Rakovina Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	25/04/22	CI
Rakovina Therapeutics Presents Preclinical Data For kt-4000 Series Compounds at AACR Annual Meeting	12/04/22	MT
Rakovina Therapeutics Presents Evaluation of A Novel Class of Bifunctional DNA Alkylating PARP Inhibitors	12/04/22	CI

Chart Rakovina Therapeutics Inc.

Duration

Period

More charts

Rakovina Therapeutics Inc. is a Canada-based biopharmaceutical company. The Company is engaged in advancing cancer therapies based on deoxyribonucleic acid (DNA)-damage response technologies. The Company has a pipeline of DNA-damage response inhibitors to advance one or more drug candidates into human clinical trials and obtain marketing approval for cancer therapeutics. The Companyâs research programs include kt-2000, kt-3000 and kt-4000. The kt-2000 next generation PARP-inhibitors. The kt-3000 class drug candidates are rationally designed to overcome treatment resistance by selectively downregulating DNA double-strand (DSB) repair mechanisms while enhancing PARP inhibitor activity. The kt-4000 series lead candidates release a potent methylation agent causing damage to a tumor cellâs DNA while also inhibiting DNA-damage repair mechanisms to cancer cell death.

Sector

Biotechnology & Medical Research

Calendar

22/05/2024 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
RAKOVINA THERAPEUTICS INC.	0.00%	4.35M
VERTEX PHARMACEUTICALS INCORPORATED	+2.97%	108B
REGENERON PHARMACEUTICALS, INC.	+10.21%	104B
ARGENX SE	+2.53%	22.33B
BIONTECH SE	-12.77%	22.19B
GENMAB A/S	-7.05%	18.69B
WUXI APPTEC CO., LTD.	-37.64%	17.74B
BEIGENE, LTD.	-6.50%	17.64B
NEUROCRINE BIOSCIENCES, INC.	+6.00%	14.05B
SAREPTA THERAPEUTICS, INC.	+37.20%	12.51B